| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nanna Thurmann Jørgensen, Trine Møller Erichsen, Morten Buus Jørgensen, Thomas Idorn, Bo Feldt-Rasmussen, Jens J Holst, Ulla Feldt-Rasmussen, Marianne Klos. Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis. Pituitary. 2023-01-07. PMID:36609655. |
the objective of the study was to describe the differential effect of various treatment regimens on the secretion of glucose, insulin, glucagon, glucagon-like peptide-1 (glp-1), and glucose-dependent insulinotropic polypeptide (gip) in patients with acromegaly. |
2023-01-07 |
2023-08-14 |
Not clear |
| Ioannis G Lempesis, Junli Liu, Maria Dalamag. The Metabolism open. vol 16. 2022-12-19. PMID:36530219. |
glp-1 and gip exert pleiotropic physiological actions, including enhancement of insulin secretion, glycemic and appetite control, cardioprotection, and adipose tissue improved function among others. |
2022-12-19 |
2023-08-14 |
Not clear |
| Rola Hammoud, Daniel J Drucke. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nature reviews. Endocrinology. 2022-12-12. PMID:36509857. |
glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp1) exhibit incretin activity, meaning that they potentiate glucose-dependent insulin secretion. |
2022-12-12 |
2023-08-14 |
Not clear |
| Imma Forzano, Fahimeh Varzideh, Roberta Avvisato, Stanislovas S Jankauskas, Pasquale Mone, Gaetano Santull. Tirzepatide: A Systematic Update. International journal of molecular sciences. vol 23. issue 23. 2022-12-11. PMID:36498958. |
gip and glp1 are incretin hormones: they are released in the intestine in response to nutrient intake and stimulate pancreatic beta cell activity secreting insulin. |
2022-12-11 |
2023-08-14 |
Not clear |
| Aya Yanagimoto, Yuji Matsui, Tohru Yamaguchi, Masanobu Hibi, Shigeru Kobayashi, Noriko Osak. Effects of Ingesting Both Catechins and Chlorogenic Acids on Glucose, Incretin, and Insulin Sensitivity in Healthy Men: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Nutrients. vol 14. issue 23. 2022-12-11. PMID:36501092. |
postprandial glucose, insulin, glucagon-like peptide-1 (glp-1), and glucose-dependent insulinotropic polypeptide (gip) responses were measured at baseline and after treatments. |
2022-12-11 |
2023-08-14 |
human |
| Vivesh, Baljit Kaur, Sombir Jaglan, Sudesh Rani, Yatin Batra, Palwinder Sing. Proline Based Rationally Designed Peptide Esters against Dipeptidyl peptidase-4: Highly Potent Anti-Diabetic Agents. Bioorganic & medicinal chemistry letters. 2022-10-09. PMID:36209967. |
since dpp-4 cleaves the glucagon like peptide (glp-1) and glucose dependent insulinotropic polypeptide (gip) hormones which are responsible for inducing insulin secretion, the results of present studies could be significant in making control over glycemia. |
2022-10-09 |
2023-08-14 |
Not clear |
| Bashaier Al-Zaid, Siby Chacko, Charles Ifeamalume Ezeamuzie, Moritz Bünemann, Cornelius Krasel, Tina Karimian, Peter Lanzerstorfer, Suleiman Al-Saba. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells. Pharmacology research & perspectives. vol 10. issue 5. 2022-09-30. PMID:36177761. |
the incretin hormones: glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) are important regulators of many aspects of metabolism including insulin secretion. |
2022-09-30 |
2023-08-14 |
Not clear |
| Giuseppe Lisco, Anna De Tullio, Olga Disoteo, Vincenzo De Geronimo, Giuseppina Piazzolla, Giovanni De Pergola, Vito Angelo Giagulli, Emilio Jirillo, Edoardo Guastamacchia, Carlo Sabbà, Vincenzo Triggian. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis. Frontiers in endocrinology. vol 13. 2022-09-26. PMID:36157450. |
basal insulin intensification with glp-1ra and dual gip and glp-1ra in patients with uncontrolled type 2 diabetes mellitus: a rapid review of randomized controlled trials and meta-analysis. |
2022-09-26 |
2023-08-14 |
Not clear |
| Giuseppe Lisco, Anna De Tullio, Olga Disoteo, Vincenzo De Geronimo, Giuseppina Piazzolla, Giovanni De Pergola, Vito Angelo Giagulli, Emilio Jirillo, Edoardo Guastamacchia, Carlo Sabbà, Vincenzo Triggian. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis. Frontiers in endocrinology. vol 13. 2022-09-26. PMID:36157450. |
herein, we overviewed the role of gip and glp-1 in the pathophysiology of type 2 diabetes and systematically reviewed the efficacy and safety of injectable incretin-based therapy added to basal insulin in light of the results of the surpass-5 trial. |
2022-09-26 |
2023-08-14 |
Not clear |
| Aleksey M Krasnyi, Alsu A Sadekova, Tatyana Y Smolnova, Vyacheslav V Chursin, Natalya A Buralkina, Vladimir D Chuprynin, Ekaterina Yarotskaya, Stanislav V Pavlovich, Gennadiy T Sukhik. The Levels of Ghrelin, Glucagon, Visfatin and Glp-1 Are Decreased in the Peritoneal Fluid of Women with Endometriosis along with the Increased Expression of the CD10 Protease by the Macrophages. International journal of molecular sciences. vol 23. issue 18. 2022-09-23. PMID:36142272. |
the aim of this study was to evaluate the levels of ten energy metabolism factors: c-peptide, ghrelin, gip, glp-1, glucagon, insulin, leptin, pai-1 (total), resistin, and visfatin, and to determine the expression of glp1r receptors, cd10, cd26 proteases, and pro-inflammatory marker cd86 by macrophages in the peritoneal fluid (pf) in patients with endometriosis. |
2022-09-23 |
2023-08-14 |
Not clear |
| Ananyaa Sridhar, Dawood Khan, Mahmoud Abdelaal, Jessie A Elliott, Violetta Naughton, Peter R Flatt, Carel W Le Roux, Neil G Docherty, Charlotte R Moffet. Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats. PloS one. vol 17. issue 9. 2022-09-22. PMID:36137097. |
insulin, glucagon, somatostatin, pyy, glp-1 and gip expression patterns were assessed using immunocytochemistry and analyzed using imagej. |
2022-09-22 |
2023-08-14 |
rat |
| Wang Shin Lei, Marissa J Kilberg, Babette S Zemel, Ronald C Rubenstein, Clea Harris, Saba Sheikh, Andrea Kelly, Joseph M Kindle. Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis. Journal of clinical & translational endocrinology. vol 30. 2022-09-16. PMID:36110921. |
gut-derived incretin hormones, including glucose-dependent insulinotropic peptide (gip) and glucagon-like peptide 1 (glp-1), regulate post-prandial glucose metabolism by promoting insulin production. |
2022-09-16 |
2023-08-14 |
Not clear |
| Wang Shin Lei, Marissa J Kilberg, Babette S Zemel, Ronald C Rubenstein, Clea Harris, Saba Sheikh, Andrea Kelly, Joseph M Kindle. Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis. Journal of clinical & translational endocrinology. vol 30. 2022-09-16. PMID:36110921. |
gip, glp-1, and insulin contribute to the acute bone anti-resorptive effect of macronutrient ingestion by modifying bone turnover. |
2022-09-16 |
2023-08-14 |
Not clear |
| Federica Ferrari, Antonio Moretti, Roberto Federico Vill. Incretin-based drugs as potential therapy for neurodegenerative diseases: Current status and perspectives. Pharmacology & therapeutics. 2022-09-05. PMID:36064147. |
however, the adverse effects of chronic insulin prompted the research of alternative strategies, such as the novel antidiabetic drugs based on the incretin hormones glucagon-like protein-1 (glp-1) and glucose-dependent insulinotropic peptide (gip). |
2022-09-05 |
2023-08-14 |
Not clear |
| Michael A Nauck, David A D'Alessi. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular diabetology. vol 21. issue 1. 2022-09-01. PMID:36050763. |
tirzepatide is an acylated peptide engineered to activate the gip and glp-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake. |
2022-09-01 |
2023-08-14 |
human |
| Joanna Goralska, Urszula Razny, Philip C Calder, Anna Gruca, Caroline E Childs, Piotr Zabielski, Aldona Dembinska-Kiec, Maciej Banach, Bogdan Solnica, Malgorzata Malczewska-Male. Glucose-Dependent Insulinotropic Polypeptide Plasma Level Influences the Effect of n-3 PUFA Supplementation. Diagnostics (Basel, Switzerland). vol 12. issue 8. 2022-08-26. PMID:36010335. |
blood analyses of glucose, insulin, non-esterified fatty acids (nefas), gip and triglycerides were performed at fasting, and during an oral glucose tolerance test and a high fat mixed-meal tolerance test. |
2022-08-26 |
2023-08-14 |
human |
| Harshit Sajal, Shashank M Patil, Ranjith Raj, Abdullah M Shbeer, Mohammed Ageel, Ramith Ram. Computer-Aided Screening of Phytoconstituents from Molecules (Basel, Switzerland). vol 27. issue 16. 2022-08-26. PMID:36014373. |
dpp4 targets and inactivates incretin hormones such as glucagon-like peptide-1 (glp-1) and gastric inhibitory polypeptide (gip) as physiological substrates, which are essential to regulate the amount of insulin that is secreted after eating. |
2022-08-26 |
2023-08-14 |
human |
| Huanqing Zhu, Kaixi Wang, Shuna Chen, Jiaxin Kang, Na Guo, Hongbo Chen, Junsheng Liu, Yuanyuan Wu, Puming He, Youying Tu, Bo L. Saponins from Nutrients. vol 14. issue 16. 2022-08-26. PMID:36014921. |
saponins from glucose-dependent insulinotropic polypeptide (gip) is one of the important incretins and possesses lots of physiological activities such as stimulating insulin secretion and maintaining glucose homeostasis. |
2022-08-26 |
2023-08-14 |
Not clear |
| Shizuka Kanek. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. TouchREVIEWS in endocrinology. vol 18. issue 1. 2022-08-11. PMID:35949358. |
however, recent studies have shown that gip has an important effect on glucagon and insulin secretion under normoglycaemic conditions. |
2022-08-11 |
2023-08-14 |
Not clear |
| Yahiya Y Sye. Tirzepatide: First Approval. Drugs. 2022-07-13. PMID:35830001. |
native gip and glp-1 are incretin hormones that stimulate insulin secretion and decrease glucagon secretion. |
2022-07-13 |
2023-08-14 |
Not clear |